Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
-
BRAF p.Gly506Val (p.G506V)
(
ENST00000288602.11,
ENST00000646891.2,
ENST00000496384.7,
ENST00000644969.2 )
BRAF p.Gly506Val (p.G506V) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumor regression. And in tumor cells of patient-derived xenograft generated from this patient, ERK signaling was sensitive to cetuximab and resistant to vemurafenib.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7552
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2222
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Panitumumab,Irinotecan
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 28783719
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Irinotecan | Sensitivity | true |
| Panitumumab | Sensitivity | true |